FEXOFENADINE HYDROCHLORIDE ALLERGY Drug Patent Profile
✉ Email this page to a colleague
When do Fexofenadine Hydrochloride Allergy patents expire, and what generic alternatives are available?
Fexofenadine Hydrochloride Allergy is a drug marketed by Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Granules, Hetero Labs Ltd V, Rising, Sciegen Pharms Inc, Sun Pharm Inds, Teva, Unique, and Wockhardt. and is included in ten NDAs.
The generic ingredient in FEXOFENADINE HYDROCHLORIDE ALLERGY is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and four suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fexofenadine Hydrochloride Allergy
A generic version of FEXOFENADINE HYDROCHLORIDE ALLERGY was approved as fexofenadine hydrochloride by TEVA on September 1st, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FEXOFENADINE HYDROCHLORIDE ALLERGY?
- What are the global sales for FEXOFENADINE HYDROCHLORIDE ALLERGY?
- What is Average Wholesale Price for FEXOFENADINE HYDROCHLORIDE ALLERGY?
Summary for FEXOFENADINE HYDROCHLORIDE ALLERGY
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 10 |
Finished Product Suppliers / Packagers: | 89 |
Raw Ingredient (Bulk) Api Vendors: | 128 |
Clinical Trials: | 79 |
Patent Applications: | 1,698 |
DailyMed Link: | FEXOFENADINE HYDROCHLORIDE ALLERGY at DailyMed |
Recent Clinical Trials for FEXOFENADINE HYDROCHLORIDE ALLERGY
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bristol-Myers Squibb | Phase 1 |
Dhaka Medical College | Phase 2/Phase 3 |
Opella Healthcare Group SAS, a Sanofi Company | Phase 3 |
Pharmacology for FEXOFENADINE HYDROCHLORIDE ALLERGY
Drug Class | Histamine-1 Receptor Antagonist |
Mechanism of Action | Histamine H1 Receptor Antagonists |